• Customer Care
  • (888) 123-4567

Business Development Director

Rise Therapeutics is recruiting a full-time business development professional to lead its partnering and corporate strategy development efforts. This position offers a unique opportunity for entrepreneurial minded professional to advance an executive-track career. The Business Development Director will be responsible for securing funding to advance innovative therapeutic programs and evolution of product development strategies. He/she will also build new relationships and establish communication networks with pharma and biotech executives to identify and execute on strategic partnership opportunities. 

 

Duties and Responsibilities

Lead sell-side partnering activities

Negotiate technology in-licensing transactions

Help set corporate strategy and execute on business-related initiatives

Negotiate productive, corporate growth-oriented deals

Research and identify new business opportunities

 

Required Qualifications

Degree (BS, MS, and/or PhD) in the life sciences and/or business administration

Strong writing, presentation, and networking capabilities

Track record of sell-side transactions

Effective communication skills with the ability to contribute in a fast-paced business environment

Comfort with collaboration in a team-based environment

Driven to translate cutting-edge technologies into life-changing products

Ability to produce results in a highly independent environment

Strong sense of responsibility for deadlines and deliverables

 

Benefits

Support initiatives to develop novel therapeutics with the potential to treat a broad range of diseases

Build business development experience working in biotechnology

Mentorship from seasoned entrepreneurs and business executives

Gain broad biotech experience in other business areas including intellectual property, tech transfer/licensing, business development, and project management

Expand network of leading academic innovators

Expand relationships/connections with leading biotechnology and pharma executives

 

Please email your CV or resume to: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About Rise Therapeutics

Rise Therapeutics is an emerging, privately held company located in Rockville, Maryland which leverages its expertise in synthetic biology and immunological drug development to create novel cellular-based immune therapies. With a strong emphasis on product development and its internal clinical GMP manufacturing infrastructure, Rise is focused on developing immunological-based biological medicines using a unique and proprietary oral biologics delivery platform. Our drug development focus is driven by new microbiome-related discoveries enabling development of targeted, first-in-class immune modulatory drugs for the treatment of inflammation, autoimmunity, cancer, and infection. In the context of its expertise in synthetic biology medicine, proprietary TPX oral drug delivery platform, and clinical GMP manufacturing capabilities, Rise is creating and rapidly advancing life changing cellular-based medicines to the market. For more information, go to www.risetherapeutics.com.  

 

Our News

Rockville, Maryland, October 19, 2023 – Rise Therapeutics, a biotechnology company engaged in developing novel oral immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a rheumatoid arthritis Phase 1 clinical trial for its program candidate, R-2487. This is Rise Therapeutics’ second clinical program developed using synthetic biology and its proprietary oral biologics delivery platform.

Biotech company receives follow-on funding to accelerate ongoing clinical development efforts

TEDCO, Maryland’s economic engine for technology companies, announced a recent Seed Funds investment of $200,000 into Rise Therapeutics, a Maryland-based biotechnology company. TEDCO’s Seed Funds invest in early-stage, technology and life sciences companies and provides access to gap financing.

 

Rockville, Maryland - Rise Therapeutics, a biotech company focused on developing novel immunological-directed synthetic biology-based therapeutics, announced today that it has received funding from the National Institutes of Health (NIH) to develop a novel therapeutic for Acute Respiratory Distress Syndrome (ARDS). The funding will support completion of product validation studies and preparation for clinical development for the program. Rise’s functionally directed immunotherapy engages natural gut microbiome-associated immunological processes with the potential to diminish lung neutrophilia, reduce inflammation, upregulate regulatory T cells, and restore airways epithelial barrier to balance and reset the patient’s immunological repertoire.